骨髓细胞改善缺血未血运重建心肌的冠脉血流储备:MiHeart/IHD定量灌注心脏磁共振亚研究
MiHeart/IHD随机试验中,78例弥漫性冠心病行不完全冠脉搭桥术的患者接受骨髓源性造血祖细胞或安慰剂心肌内注射,并完成1、6、12个月的心脏磁共振灌注定量。共分析1248个节段,靶区(注射区)基线冠脉血流储备显著低于邻近区和远隔区;骨髓细胞组靶区及邻近区冠脉血流储备在6和12个月较安慰剂组显著升高,靶区疗效递增至12个月(6个月27.1%,12个月42.2%),远隔区两组改善相似且12个月时与基线比无显著差异。
要点
- 靶区(注射区)基线冠脉血流储备显著低于邻近区和远隔区(1.40±0.79 vs 1.64±0.89和1.79±0.79,均P<0.05)。
- 骨髓细胞组靶区冠脉血流储备较安慰剂组在6个月增加27.1%(P=0.037)、12个月增加42.2%(P=0.001),呈递增疗效。
- 邻近区骨髓细胞组冠脉血流储备6个月增加21.8%(P=0.023)、12个月增加22.6%(P=0.022);远隔区两组改善相似,12个月与基线比无显著差异。
核心结论
- 在不适于直接血运重建的严重缺血区域注射骨髓源性造血祖细胞,可带来最大的冠脉血流储备改善并持续进展至12个月,邻近区有较小但持续的改善,远隔区无改善。
研究设计与样本
- MiHeart/IHD随机对照试验的定量灌注心脏磁共振亚研究,78例弥漫性冠心病行不完全冠脉搭桥术的患者随机接受骨髓源性造血祖细胞或安慰剂心肌内注射,于术后1、6、12个月行心脏磁共振检查。
关键影像表现/征象
- 共分析1248个节段,其中靶区269个(22%)、邻近区397个(32%)、远隔区582个(46%)。
- 靶区基线冠脉血流储备为1.40±0.79,显著低于邻近区的1.64±0.89和远隔区的1.79±0.79(均P<0.05)。
诊断标准与关键数值
- 靶区骨髓细胞组较安慰剂组冠脉血流储备6个月增加27.1%(P=0.037)、12个月增加42.2%(P=0.001)。
- 邻近区骨髓细胞组较安慰剂组冠脉血流储备6个月增加21.8%(P=0.023)、12个月增加22.6%(P=0.022)。
- 远隔区骨髓细胞组与安慰剂组冠脉血流储备改善相似,12个月与基线比无显著差异。
临床应用与阅片要点
- 定量灌注心脏磁共振可将心肌节段分为靶区(注射区)、邻近区(注射部位周围)和远隔区,用于评估区域灌注储备变化。
- 靶区基线冠脉血流储备低于邻近区和远隔区,提示注射区域为缺血更重的靶区。
- 骨髓细胞组靶区和邻近区冠脉血流储备在6和12个月较安慰剂组升高,靶区疗效随时间递增至12个月,远隔区两组改善相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study investigated whether intramyocardial bone marrow-derived hematopoietic progenitor cells (BMCs) increase coronary flow reserve (CFR) in ischemic myocardial regions where direct revascularization was unsuitable.
BACKGROUND: Patients with diffuse coronary artery disease frequently undergo incomplete myocardial revascularization, which increases their risk for future adverse cardiovascular outcomes. The residual regional ischemia related to both untreated epicardial lesions and small vessel disease usually contributes to the disease burden.
METHODS: The MiHeart/IHD study randomized patients with diffuse coronary artery disease undergoing incomplete coronary artery bypass grafting to receive BMCs or placebo in ischemic myocardial regions. After the procedure, 78 patients underwent cardiovascular magnetic resonance (CMR) at 1, 6, and 12 months and were included in this cardiac magnetic resonance substudy with perfusion quantification. Segments were classified as target (injected), adjacent (surrounding the injection site), and remote from injection site.
RESULTS: Of 1,248 segments, 269 were target (22%), 397 (32%) adjacent, and 582 (46%) remote. The target had significantly lower CFR at baseline (1.40 ± 0.79 vs 1.64 ± 0.89 in adjacent and 1.79 ± 0.79 in remote; both P < 0.05). BMCs significantly increased CFR in target and adjacent segments at 6 and 12 months compared with placebo. In target regions, there was a progressive treatment effect (27.1% at 6 months, P = 0.037, 42.2% at 12 months, P = 0.001). In the adjacent segments, CFR increased by 21.8% (P = 0.023) at 6 months, which persisted until 12 months (22.6%; P = 0.022). Remote segments in both the BMC and placebo groups experienced similar improvements in CFR (not significant at 12 months compared with baseline).
CONCLUSIONS: BMCs, injected in severely ischemic regions unsuitable for direct revascularization, led to the largest CFR improvements, which progressed up to 12 months, compared with smaller but persistent CFR changes in adjacent and no improvement in remote segments.
引用
- Assuncao-Jr AN, Rochitte CE, Kwong RY, et al. Bone Marrow Cells Improve Coronary Flow Reserve in Ischemic Nonrevascularized Myocardium: A MiHeart/IHD Quantitative Perfusion CMR Substudy. JACC Cardiovasc Imaging. 2022. PMID: 35512954. doi:10.1016/j.jcmg.2021.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。